胃と腸46巻7号

2011年06月発行

今月の主題 腸管Behçet病と単純性潰瘍─診断と治療の進歩 主題関連研究

腸管Behçet病に対するサイトカイン療法の基礎研究

著者： 岳野光洋¹ 石ヶ坪良明¹

所属機関： ¹横浜市立大学病態免疫制御内科学

ページ範囲：P.1073 - P.1080

要旨　Behçet病は，HLA-B51をはじめとした遺伝素因に環境因子が付加され，免疫異常を引き起こし発症に至ると考えられている．最近のGWASでIL10，IL23R-IL12RB2が新たな遺伝素因として同定され，Th1，Th17型自己免疫応答が病態に関与することが改めて認識された．一方で，好中球機能過剰，TLR発現異常などの自然免疫異常も病態にかかわることも示されている．抗腫瘍壊死因子-α抗体は高い効果を示すが，現状では効果の持続に問題がある．また，インターフェロン-αは長期的に安定した効果を示すが，まだ，その薬理効果の発現機序は解明されていない．これらの課題の解決により病態はさらに明らかになるものと思われる．

参考文献

1）Sakane T, Takeno M, Suzuki N, et al. Current concepts : Behçet's disease. N Engl J Med 341 : 1284-1291, 1999

2）de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet's disease : a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61 : 1287-1296, 2009

3）Yasuoka H, Okazaki Y, Kawakami Y, et al. Autoreactive CD8＋cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behçet's disease. Arthritis Rheum 50 : 3658-3662, 2004

4）Kaneko S, Suzuki N, Yamashita N, et al. Characterization of T cells specific for an epitope of human 60-kD heat shock protein（hsp）in patients with Behcet's disease（BD）in Japan. Clin Exp Immunol 108 : 204-212, 1997

5）Brand S. Crohn's disease : Th1, Th17 or both ? The change of a paradigm : new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58 : 1152-1167, 2009

6）Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 42 : 703-706, 2010

7）Remmers EF, Cosan F, Kirino Y, et al, Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 42 : 698-702, 2010

8）Kirino Y, Takeno M, Watanabe R, et al. Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behçet's disease. Arthritis Res Ther 10 : R16, 2008

9）Horie Y, Meguro A, Ota M, et al. Association of TLR4 polymorphisms with Behcet's disease in a Korean population. Rheumatology（Oxford） 48 : 638-642, 2009

10）Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nature Med 8 : 240-246, 2002

11）Kirino Y, Takeno M, Murakami S, et al. Tumor necrosis factor-alpha acceleration of inflammatory responses by down regulating heme oxygenase-1 in human peripheral monocytes. Arthritis Rheum 56 : 464-475, 2007

12）Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol 139 : 371-378, 2005

13）Nara K, Kurokawa MS, Chiba S, et al. Involvement of innate immunity in the pathogenesis of intestinal Behçet's disease. Clin Exp Immunol 152 : 245-251, 2008

14）Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67 : 1656-1662, 2008

15）Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol. in press

16）Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine 24 : 210-218, 2003

17）Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of Interferon-αtreatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 62 : 2796-2805, 2010

18）Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60 : 1785-1796, 2009

19）Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 14 : 1259-1264, 2008

20）Iwata S, Saito K, Yamaoka K, et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology 48 : 1012-1013, 2009